Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04471779). This is a study registration, not published results. Lead sponsor: Columbia University. Recruitment status: COMPLETED. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 374 participants (ACTUAL). Conditions: Alzheimer Disease. Interventions: OTHER: Disclosure of APOE genotype. Primary outcome measures: Impact of Genetic Testing in AD (IGT-AD) , 6 weeks after risk evaluation; Impact of Genetic Testing in AD (IGT-AD) , 9 months after risk evaluation; Impact of Genetic Testing in AD (IGT-AD) , 15 months after risk evaluation; Impact of Event Scale-Revised , 6 weeks after risk evaluation; Impact of Event Scale-Revised , 9 months after risk evaluation; Impact of Event Scale-Revised , 15 months after risk evaluation; Change in Score on the Brief Test of Adult Cognition by Telephone (BTACT) , Baseline and 6 weeks after risk evaluation; Change in Score on the Brief Test of Adult Cognition by Telephone (BTACT) , Baseline and 9 months after risk evaluation; Change in Score on the Brief Test of Adult Cognition by Telephone (BTACT) , Baseline and 15 months after risk evaluation; Change in Score on the Metamemory in Adulthood Questionnaire-Revised , Baseline and 6 weeks after risk evaluation; Change in Score on the Metamemory in Adulthood Questionnaire-Revised , Baseline and 9 months after risk evaluation; Change in Score on the Metamemory in Adulthood Questionnaire-Revised , Baseline and 15 months after risk evaluation. Brief summary: This study will assess the psychosocial and behavioral impacts of receiving Alzheimer's disease genetic risk assessment incorporating APOE genotypes among Latinos in northern Manhattan. The investigators will conduct a longitudinal, community-based study with a mixed methods design. Participants will be randomized to learn about their lifetime risk of late-onset Alzheimer's disease (AD) based either on (a) Latino ethnicity and family history alone (genotype nondisclosure group), or (b) the same factors plus APOE genotype (genotype disclosure group). Responses will be evaluated at 6 weeks, 9 months, and 15 months after risk assessment. In the quantitative component of the study, the investigators will assess psychosocial outcomes, memory test performance, and health-related behaviors. In the qualitative component of the study, the investigators will investigate the lived experience of receiving personal AD risk information, using a stress and coping theoretical framework.